OrthoPediatrics Corp. (Nasdaq: KIDS), a medical device company focused on pediatric orthopedics, reported revenue of $236.3 million for the year ended December 31, 2025, a 15% increase compared to $204.7 million in 2024. The company's growth was primarily driven by strong performance across its global Trauma and Deformity, Scoliosis, and OP Specialty Bracing segments, as well as contributions from recent acquisitions. Cost of revenue was $63.7 million, resulting in a gross margin of 73%, consistent with the prior year. The company's operating loss was $39.2 million, compared to $35.0 million in the previous year.
The company's Trauma and Deformity segment, which includes acquired businesses, saw revenue increase by 15% to $166.3 million, driven by growth in Cannulated Screws, PNP Femur, PediPlate, external fixation, and Pega systems. Scoliosis revenue increased by 20% to $66.0 million, primarily due to increased sales of RESPONSE 5.5/6.0 and 7D Technology. Sports Medicine/Other revenue decreased by 10% to $4.0 million. Sales and marketing expenses increased by 13% to $72.7 million, primarily due to higher sales commission expenses. General and administrative expenses increased by 17% to $119.8 million, driven by acquisitions and higher stock-based compensation.
OrthoPediatrics experienced several strategic developments during the year, including acquisitions of orthotic and prosthetic device clinics in Ireland, and a designer and manufacturer of clubfoot bracing in the UK. The company also established a legal entity in Brazil to sell and distribute directly to the local market. In addition, the company continued to invest in research and development, with a focus on new implant and bracing systems, line extensions, and product improvements. Research and development expenses decreased by 18% to $9.1 million.
As of December 31, 2025, OrthoPediatrics had cash, cash equivalents, and restricted cash of $21.6 million and short-term investments of $41.3 million, totaling $62.9 million. The company's largest investor is Squadron, a private investment firm. The company's workforce consisted of 602 full-time equivalent employees. The company's long-term debt consisted of a term loan of $48.2 million and convertible notes of $48.5 million. The company's strategy includes focusing on high-volume children's hospitals, providing a broad product portfolio, deploying instrument sets, expanding its addressable market through research and development and acquisitions, and training the next generation of pediatric orthopedic surgeons. The company's net loss was $39.6 million, or $1.69 per share, compared to a net loss of $37.8 million, or $1.64 per share, in the previous year.
About ORTHOPEDIATRICS CORP
OrthoPediatrics Corp. specializes in designing, developing, and marketing pediatric-specific orthopedic implants, instruments, and braces for trauma, deformity correction, scoliosis, and sports medicine. Serving hospitals worldwide, it supports pediatric surgeons through dedicated sales, clinical education, and research collaborations. Its comprehensive product portfolio addresses unmet needs in children’s orthopedic care, leveraging innovation, strategic acquisitions, and a focus on improving young patients' outcomes.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.